Article Sidebar

PDF
Date Published: 02/01/2024
Abstract Views: 128
Views PDF: 122
DOI: https://doi.org/10.51298/vmj.v533i1.7755
Issue
Vol. 533 No. 1 (2023)
Section
Các bài báo
How to Cite
Đỗ , A. T. ., & Dương , T. L. . (2024). SIDE EFFECTS OF DOCETAXEL - PREDNISOLONE REGIMEN ON PATIENTS WITH ORCHIECTOMY-RESISTANT PROSTATE CANCER. Vietnam Medical Journal, 533(1). https://doi.org/10.51298/vmj.v533i1.7755

SIDE EFFECTS OF DOCETAXEL - PREDNISOLONE REGIMEN ON PATIENTS WITH ORCHIECTOMY-RESISTANT PROSTATE CANCER

Anh Tú Đỗ , Thị Lệ Dương

Main Article Content

Abstract

Background: The main reported adverse effects of the docetaxel plus prednisone regimen were leukopenia (10%), vomiting (32%), and diarrhea (12%). Drug toxicity is tolerable. Objective: To evaluate the side effects of castration-resistant prostate cancer patients treated with Docetaxel-Prednisolone regimen. Research subjects and methods: Cross-sectional analysis of adverse effects of chemotherapy in 31 CRPC patients. Results: On the hematopoietic system, the most common toxicities are anemia (61.3% of patients) and leukopenia (38.7%), however, toxicities are mainly seen at level 1- 2, the rate of grade 3-4 leukopenia is 3.2% and can be controlled. Hepatotoxicity (29%) and kidney (22.6%) were mild. Conclusion: Chemotherapy with docetaxel –prednisolone is a safe and effective regimen in the treatment of castration-resistant prostate cancer.

Article Details

References

1. I. F. Tannock, et al., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 2004. 351(15): p. 1502-12.
2. Bùi Văn Kiệt, Trần Minh Anh Thư, Nguyễn Mạnh Tiến và CS., Đánh giá hiệu quả phác đồ Docetaxel + Prednisolon trong điều trị ung thư tuyến tiền liệt kháng cắt tinh hoàn tại bệnh viện Bình Dân. Tạp chí Y Học TP. Hồ Chí Minh, 2014. 18.
3. L. Lee, et al., Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea. Cancer Res Treat, 2010. 42(1): p. 12-7.
4. S. Naito, et al., Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Jpn J Clin Oncol, 2008. 38(5): p. 365-72.
5. I. C. Cho, et al., Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea. J Cancer Res Ther, 2014. 10(2): p. 251-7.
6. E. Tomassini, et al., Fulminant hepatocellular necrosis following administration of docetaxel. Presse Med, 2001. 30(13): p. 634.
7. D. P. Petrylak, et al., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 2004. 351(15): p. 1513-20.